This 12 months’s J.P. Morgan Healthcare Convention in San Francisco, which wrapped on Thursday, enabled healthcare leaders from everywhere in the nation to convene, have discussions and community. The occasion additionally featured a slew of stories bulletins from firms everywhere in the healthcare sector.
Under are seven notable bulletins made through the convention.
Mayo Clinic forges AI collaboration with Cerebras Programs
Mayo Clinic launched a partnership with Silicon Valley-based AI agency Cerebras Programs to develop new AI fashions for healthcare use circumstances. Mayo plans to use Cerebras’ computing chips and methods to the well being system’s wealth of anonymized medical data and knowledge, which spans a number of a long time.
The well being system stated that the AI fashions developed below this partnership will carry out a variety of features. For instance, some instruments will be capable of generate summaries of key data from new sufferers’ medical data. Others might be able to shortly study genome knowledge or scrutinize medical photographs to determine patterns which will elude the human eyes of educated medical professionals.
Mayo famous these new AI fashions won’t make medical choices, because the accountability for such judgments will proceed to relaxation with medical doctors. The brand new fashions will ultimately turn out to be accessible on Mayo Clinic Platform, an information community utilized by well being methods within the U.S. and overseas.
Boston Scientific to accumulate Axonics for $3.7 billion
Boston Scientific introduced its plan to accumulate Axonics, a maker of neurostimulation gadgets that deal with urinary and bowel dysfunction, for $3.7 billion. Specialists agree that this deal will make a worthwhile influence on Boston Scientific’s urology enterprise.
Axonics presents each rechargeable and recharge-free implants for sacral neuromodulation — a minimally invasive process that treats overactive bladder and bowel incontinence. This sort of remedy delivers gentle electrical pulses to the sacral nerves, which management the bladder, bowel and pelvic ground muscular tissues. This modulation helps regulate and normalize nerve signaling — resulting in improved coordination of bladder and bowel actions, lowered urinary incontinence and alleviation of signs related to pelvic ground dysfunction.
The deal is the most recent in a string of acquisitions Boston Scientific has made prior to now two years. In 2022, the corporate introduced acquisitions of hydrogel maker Obsidio, endoscopy machine producer Apollo Endosurgery and cardiovascular therapy machine firm Acotec Scientific. Final 12 months, the corporate purchased Relievant Medsystems, which makes gadgets for power again ache.
Amazon launches a program selling digital well being advantages
Amazon rolled out a new initiative to assist join folks to digital well being advantages that they could not know can be found to them by their employer or well being plan. To take action, Amazon plans to companion with digital well being firms providing applications that assist handle power situations like diabetes and hypertension.
Amazon’s first companion for this new program is Omada Well being — a San Francisco-based startup that gives digital look after diabetes prevention, weight administration, diabetes and hypertension.
When Amazon prospects seek for a tool like a blood stress monitor or blood glucose meter, they may see a notification alerting them that they could be eligible to hitch a power situation administration program for free of charge. Customers can then go to the Amazon Well being webpage to examine if their employer or well being plan has made Omada’s applications accessible to them. In the event that they want to take part, Amazon will information them to Omada’s web site to finish their enrollment.
U.S. workers go away about 30% of their complete compensation on the desk by not using the advantages which might be accessible to them, Amazon identified in its announcement.
Johnson & Johnson to purchase Ambrx for $2 billion
Johnson & Johnson reached a $2 billion deal to accumulate clinical-stage Ambrx Biopharma. The deal is without doubt one of the many acquisitions that massive pharmaceutical firms have made prior to now few years within the antibody drug conjugate (ADC) house.
ADCs are a well-liked goal for pharma acquisitions as a result of they boast promising potential to make most cancers therapy simpler. These medication ship poisonous payloads on to most cancers cells, aiming to attenuate injury to wholesome cells and enhance precision when attacking tumors.
Ambrx’s lead program targets the protein PSMA and is at present in Part 1 testing for superior prostate most cancers. In November, the corporate reported promising knowledge from a dose-escalation research and stated it expects to have a advisable dose for Part 2 testing in early 2024.
Abbott’s diabetes care unit declares first insulin pump integration within the U.S.
Abbott’s diabetes care enterprise introduced the combination of its FreeStyle Libre 2 Plus steady glucose monitor into Tandem Diabetes Care’s t:slim X2 insulin pump.
Abbott’s up to date steady glucose monitor was cleared by the FDA to be used with automated insulin supply in March of final 12 months. The JPM announcement marks the primary automated insulin supply system to combine Abbott’s new FreeStyle Libre 2 Plus sensor.
This announcement comes a month after Tandem grew to become the primary firm to combine with Dexcom’s newest steady glucose monitor.
Merck buys Harpoon Therapeutics for $680 million
Merck introduced that it’ll purchase Harpoon Therapeutics, a developer of focused most cancers therapies, for $680 million. Harpoon conducts analysis on T cell engagers, a class of medicine that activate T cells to kill most cancers cells.
In contrast to typical T cell engagers, Harpoon’s medication not solely bind to a T cell and a most cancers cell, but in addition incorporate a site that extends the remedy’s half-life. The corporate’s lead drug candidate is designed to focus on DLL3, a most cancers protein expressed at excessive ranges in small cell lung most cancers and neuroendocrine tumors. The drug is in Part 1/2 testing as a monotherapy in sufferers with superior cancers that categorical the DLL3 protein.
Innovaccer launches generative AI-based scientific documentation instrument
Innovaccer unveiled Sara Scribe, an AI resolution designed to fight skilled burnout. The AI assistant transcribes after which summarizes key data from the conversations held between suppliers and sufferers.
The instrument not solely analyzes patient-provider conversations — it additionally guarantees to make use of EHR and claims knowledge to flag potential coding gaps, high quality gaps and diagnoses.
Picture: Getty Pictures, Digital Imaginative and prescient
Supply hyperlink
